Probiotics as vehicles for vaccine administration

我们已经使用SIV Gag蛋白作为模型抗原来测试这种实验方法。在指定的载体上制备重组Gag蛋白，并将其与嗜酸乳杆菌混合。观察了Gag蛋白与细菌的结合，并通过3周的时间给小鼠灌胃+/-SIV Gag蛋白。免疫后2周或3周，4只小鼠中有2只出现较强的抗体反应。基于这种阳性反应，我们正在开发重组肿瘤抗原融合蛋白，即TARP和K-ras，以评估当这些抗原呈现在乳杆菌表面时宿主对这些抗原的反应。一旦产生了合适的重组基因，我们将确定小鼠是否可以免受KRAS驱动的肿瘤的影响。

We have tested this experimental approach by using the SIV GAG protein as a model antigen. Recombinant GAG protein was prepared in the designated vector and the fusion protein obtained was mixed with Lactobacillus acidolphilus. Binding of the GAG protein to the bacteria was observed and mice were administered the microorganisms +/- the SIV GAG protein via stomach gavage over a 3 week period. A strong antibody response was observed in 2 of 4 treated mice after 2 or 3 weeks of immunization. Based on this positive response, we are developing recombinant tumor antigen fusion proteins, i.e. TARP and K-ras, in order to evaluate the host response to these antigens when presented on the surface of Lactobacillus. Upon creation of the appropriate recombinant we will determine if the mice can be protected from KRAS driven tumors.